Anyone drafting patent licence agreements should follow several tips in order to avoid or better prepare for litigation later on, says Jessamyn Berniker of Williams & Connolly.
Several changes have been made to Italy’s regulatory landscape for biosimilars, as Luca Tosoni of Covington & Burling reports.
A combination of patents, SPCs and regulatory exclusivities should be considered carefully in order to maximise the exclusivity available for cell therapies, as Glyn Truscott of Elkington + Fife explains.
Anyone seeking a deal with a life sciences company must understand the value and potential risks of its IP, as Karen Mangasarian and Ryan Murphey of Ropes & Gray explain.
The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.
Two bodies are responsible for examining biotech patent applications in Brazil, but this approach causes problems, as Marcelo Oliveira de Souza and Antonio Alexandre Moura dos Santos of Di Blasi, Parente & Associados report.
With specialist IP providers offering post-M&A services at lower cost than traditional law firms, have clients been overspending in the past? Melissa Pillote on behalf of Dennemeyer reports.
There is some debate among Russian legal professionals about whether “selection inventions” are considered patentable, but the answer seems clear, says Valery Djermakian of Gorodissky & Partners.
‘Technological intelligence’ is very important for extracting maximum value from technology transfer deals, and life sciences companies should use it to their advantage, says Montserrat González-Álvarez of Leyva, Montenegro, Trigueros Abogados.
New legislation in Brazil aims to create a balance between using genetic resources for scientific advancement and spreading the benefits among local communities fairly, as Gabriel Di Blasi of Di Blasi, Parente & Associados and Eduardo Emrich of Biominas Brasil explain.